![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnrd4326/MediaObjects/41573_2014_Article_BFnrd4326_Fig1_HTML.jpg)
Change history
04 July 2014
In the text of the article, cobimetinib was incorrectly described as a BRAF inhibitor, but is actually a MEK inhibitor. The online version of the article has been corrected accordingly.
References
Decision Resources Group. Malignant Melanoma (Pharmacor; 2013–2014).
Decision Resources Group. Immunotherapies (Pharmacor; 2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Webster, R., Mentzer, S. The malignant melanoma landscape. Nat Rev Drug Discov 13, 491–492 (2014). https://doi.org/10.1038/nrd4326
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4326
- Springer Nature Limited
This article is cited by
-
A new glance at autophagolysosomal-dependent or -independent function of transcriptional factor EB in human cancer
Acta Pharmacologica Sinica (2023)
-
Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
Acta Neuropathologica Communications (2019)
-
Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma
Scientific Reports (2016)
-
Compound 13, an α1-selective small molecule activator of AMPK, potently inhibits melanoma cell proliferation
Tumor Biology (2016)
-
Adolescent and young adult patients with cancer: a milieu of unique features
Nature Reviews Clinical Oncology (2015)